Departments of Physiology and Veterinary Biomedical Sciences and Dalton Cardiovascular Research Center, University of Missouri, Columbia, Missouri 65212
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Sensitivity of endothelin-1 (ET-1)-ion channel interactions has
been proposed to exceed that of ET-1-phospholipase activation in
vascular smooth muscle. We wanted to determine whether short-circuiting ion channels with staphylococcal -toxin pores would shift the ET-1-force relation to the right as predicted from the above proposal. Medium size porcine coronary arteries (outer diameter 0.7-1.5 mm)
were mounted on isometric force transducers. ET-1 concentration response curves were compared between intact rings and those subjected to
-toxin treatment with Ca buffered at 0.1 µM. The
EC50 for treated rings (1.5 ± 1.0 nM, n = 5 pigs) was similar to
that for intact rings (1.9 ± 0.4 nM). The Ca sensitivity of the
-toxin-treated rings
(EC50 = 0.43 ± 0.08 µM) was similar to that reported by other laboratories for intact and
-toxin-treated arteries and was shifted eightfold to the left by a
high concentration of ET-1 (10 nM). Measurements of
[32P]phosphatidic acid
([32P]PA) levels were
used to evaluate phospholipase activity in intact arteries. The time
courses for [32P]PA
production and contraction were similar in response to high (100 nM)
and to low (1 nM) ET-1. Significant increases in both steady-state
contraction and
[32P]PA occurred over
a wide range of ET-1 concentrations tested (0.3-100 nM). Our
findings support the concept that ET-1-phospholipase coupling is
operative over the whole concentration range that induces contractile
responses. It is suggested that both Ca entry and Ca sensitization
processes are activated by ET-1 at low concentrations (<EC50) and that both
processes contribute significantly to the integrated response.
contraction; phosphatidic acid; calcium sensitivity; staphylococcal
-toxin; vascular smooth muscle
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
THE POTENT AGONIST endothelin-1 (ET-1) activates vascular smooth muscle by a combination of increased cytosolic Ca activity [cytosolic Ca concentration ([Ca]i)] and sensitization of the contractile system to [Ca]i (35, 46). Much evidence supports the concept that ET receptors are coupled to mechanisms that increase Ca entry, stimulate Ca release from sarcoplasmic reticulum (SR), and shift the Ca-force relation curves to the left in intact vascular smooth muscle cells (23, 27, 61). It has been proposed that ET receptors interact via G protein linkages with 1) membrane ion channels and 2) membrane phospholipases such as phospholipase C (PLC) and phospholipase D (PLD) (35, 46). The first process would stimulate Ca entry via voltage-sensitive mechanisms and would be inhibited by Ca channel antagonists or stimulated by membrane depolarization (24). The second process would stimulate the production of second messengers that are associated with Ca release from SR and increased sensitivity of the Ca-force relation (12, 35, 40, 46).
It has been proposed that the sensitivity of ET-1-channel interactions
significantly exceeds that of phospholipase activation (9, 24, 35, 40).
For instance, contractions caused by low concentrations of ET are
sensitive to Ca channel blockers that shift the ET-force relation
curves to the right (i.e., EC50 from 1 to 10 nM) (24, 61). Also, elevated extracellular K concentration
shifted the response to the left
(EC50 0.1 nM) (24). By
inference, the ET-force relation in the presence of maximal Ca channel
blockade would represent the dependence of force development on the
coupling between ET-1 and phospholipase activity leading to SR Ca
release and sensitization. In the presence of an intact sarcolemma,
however, the control of
[Ca]i is problematic. Also, Ca channel blockers were shown to depress SR Ca release in
vascular smooth muscle made permeable with staphylococcal
-toxin (26). Because SR Ca release relied on PLC activation, the results derived from Ca channel blockers may not be specific for membrane Ca
channel effects.
An alternative approach to the use of Ca channel blockers is to
permeabilize the surface membrane with -toxin, thereby circumventing problems associated with sarcolemmal Ca control. After treatment with
-toxin, receptor-second messenger signaling mechanisms (referred to
as pharmacomechanical coupling) remain functional, thus allowing Ca
sensitization to occur, while
[Ca]i can be
controlled by a Ca-buffer solution (26, 42). Importantly, the pores
formed by
-toxin short-circuit the contribution of Ca channels and
thus obviate the use of Ca channel blockers. Under these conditions, ET-1 was shown to increase the Ca sensitivity of the contractile system; however, only high concentrations of ET-1 were used (>10 nM)
(14, 42, 57). A similar shift in Ca sensitivity also was observed in
arteries permeabilized with
-escin and exposed to a high
concentration of ET (10 nM) (63). It was our objective to determine
whether short-circuiting Ca channels with
-toxin pores would shift
the ET-force curves to the right as predicted from the proposal that
phospholipase coupling mechanisms are less sensitive to ET-1 than are
channel mechanisms (9, 12, 24, 35). We hypothesized that no shift in
this relation would occur after treatment with
-toxin because ET-1
stimulation of phospholipase products in intact cells often exhibited
sensitivities similar to those of ET-1-force relations (31, 44, 48).
Hence, ET-phospholipase coupling is functional over physiologically
relevant concentrations.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Tissues. Branches (outer diameter 0.7-1.5 mm, measured by a scale in the dissection microscope) of the major coronary arteries from pigs were trimmed of loose connective tissue, nerves, and vasa vasorum in a dissection solution at room temperature. This was followed by incubation at 35°C in a physiological salt solution (PSS) gassed with air. The hearts (maintained in ice-cold dissection solution during transit) were obtained from slaughterhouse pigs and from anesthetized female Yucatan pigs at the University of Missouri. The contractile sensitivity to ET-1 was similar in arteries from these two sources, as well as in vessels used after overnight cold storage (unpublished observations). For contractile studies, rings (outer diameter 0.7-1.1 mm, wall thickness ~0.10-0.14 mm, and length 0.3-1.0 mm) were denuded of endothelium by rotating them over silk suture. They were mounted on a force transducer (Grass) with an attached micrometer drive and were stretched to 1.4 times the resting length. All rings were tested with a high-K solution (80 mM K, substituted for Na) to establish a reference contracture. Siliconized cups were used to hold solutions that contained ET-1. Arteries used for phosphatidic acid (PA) assay were mounted on wires to facilitate handling.
Reagents and solutions.
Normal PSS had a composition (in mM) of 132 NaCl, 5 KCl, 1.5 CaCl2, 1.2 MgCl2, 1.2 NaH2PO4,
10 Na-HEPES (pH 7.4), and 11.2 glucose. The dissection and the
PO4-free solutions were the same, except that the former contained low Ca (0.2 mM) and that
PO4 was omitted from the latter.
The relaxing solution (R2) used
for the permeabilization study was composed of (in mM) 130 potassium propionate, 4 MgCl2, 20 K-PIPES
(pH 7.0), 2 K-EGTA, 4 Na2ATP, 20 creatine phosphate, 0.001 FCCP (a mitochondrial inhibitor), and
11.4 glucose. The desired free Ca was achieved by adding
calcium propionate on the basis of calculations using a computer
program provided by Dr. R. Moreland (37). ET-1 was purchased from
Peninsula Laboratory and diluted in 10 mM acetic acid. Staphylococcal
-toxin was obtained from LIST and was diluted in deionized water.
Other biochemical compounds were purchased from Sigma.
Permeabilization protocol.
After the intact rings recovered from K depolarization, they were
placed into 5 ml R2 (~0 Ca) for
30 min at 35°C. A transient contraction occurred, which may reflect
the action of ATP on purinergic receptors that eventually desensitize
(39). This procedure also reduced Ca stores, since control experiments
showed that maximal ET-1 produced no contracture after 30 min in
R2 (unpublished observation). Rings then were transferred for 30 min into a similar solution (300 µl) containing -toxin (30-50 µg/ml) and 10 mM sodium azide to inhibit ecto-ATPase activity (58). We did not use 5 mM DIDS as
recommended (58) because control experiments showed that DIDS inhibited
greatly the contractile response of permeabilized preparations
(unpublished observations). The rings were transferred to fresh
R2, and the addition of
experimental agents was commenced after 30 min. The concentration of
ATP in the R2 solution (analyzed by the chromatography core laboratory at Dalton Cardiovascular Research
Center) was 4.0 mM after 30 min of the permeabilization protocol,
compared with 4.3 mM in an unused sample. During the experiments, we
kept the volume of R2 high (5 ml)
compared with the tissue size (0.5 µl) to ensure constant ATP in the
solutions.
PA assay. Arteries were labeled with 32PO4 (50 µCi/ml in PO4-free PSS) for 2 h at 35°C. The segments were placed in nonlabeled solutions 10 min before exposure to ET-1. Arteries were then freeze clamped and placed immediately into 3 ml chloroform-methanol (1:2 vol/vol) for PA extraction and processing (22). The lipid phase was dried, resuspended in 30 µl chloroform, and spotted onto a Whatman LKGD plate (Whatman Lab). The plate was developed using a TLC solvent system of chloroform-pyridine-88% formic acid (10:6:1 vol/vol/vol). PA was separated with a retardation factor of 0.5 that was identified by standards (Sigma) (22). 32P was measured by means of a storage phosphor screen exposed to the TLC plate for 2 h. The screen was scanned on a Molecular Dynamics PhosphorImager and analyzed using Molecular Dynamics software. The PA values were expressed as a percentage of total 32P counts per lane.
Data analyses. The contractile responses were normalized in terms of maximal response to ET-1. The excitatory concentration causing a 50% response (EC50) was determined for each ring by linear interpolation between the logarithms of concentrations that produced responses just below and above 50%. Because the EC50 values were normally distributed on a logarithmic rather than arithmetic scale, logarithmic values were used to make statistical comparisons. These were transformed to arithmetic means for presentation in the text. Student's t-test was used to test for differences between group means, with P < 0.05 taken to be significant.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Contractile responses of intact and permeabilized rings.
Rings treated with -toxin exhibited stable re-sponses
to ET-1 and to Ca as shown in Fig. 1.
During our preliminary experiments, we found it necessary to add GTP to
R2 to sensitize the contractile responses to ET-1, consistent with a previous report (42). It is
significant that cumulative addition of ET-1 caused progressive force
development in the presence of 0.1 µM Ca (Fig.
1A). This concentration simulated
basal [Ca]i in intact
porcine coronary arteries (measured by fura 2) and was not associated
with significant force development (29). Maximal force was not achieved
by high ET-1 (30 nM) at 0.1 µM Ca, and subsequent addition of Ca to 3 µM resulted in a maximal response (Fig.
1A). This response and that to 10 µM Ca alone (Fig. 1B) exceeded the
response to high K in intact rings. Cumulative addition of Ca in the
absence of ET-1 also caused progressive increases in contraction (Fig.
1B). The averaged responses, as
shown in Fig. 2, exhibited a sharp increase
in slope between 0.2 and 1 µM Ca (log[Ca] =
6.70
to
6.00). The EC50 of 0.43 ± 0.08 µM (log[Ca] =
6.37) was similar to that
reported for rabbit mesenteric and canine basilar arteries treated with
-toxin (42, 57) and to that observed in intact porcine coronary
arteries (29). Measures of contraction and Ca activity (fura 2 method)
during K depolarization showed half-maximal contraction at a
[Ca]i equivalent to
0.39 µM (log[Ca] =
6.41; see Fig.
2C in Ref. 29). As noted above, we
chose an EGTA concentration (2 mM) that would maintain a
relatively normal sensitivity of the contractile system to Ca. It was
important not to increase inadvertently the Ca sensitivity of the
coronary arteries by the conditions employed in the
-toxin protocol.
|
|
|
PA acid production. Measures of ET-1 effects on [32P]PA levels were used to evaluate phospholipase activity. PA responses to ET-1 and other agonists have been shown to be sensitive indicators of PLC by the conversion of its product, diacylglycerol (DAG), to PA and also of PLD, which produces PA directly (21, 22, 31). The phosphor image measurements in these studies allowed [32P]PA to be identified (Fig. 4) and quantitated in the same step. This procedure eliminated the need to scrape the TLC plates for 32P counting as was done previously (21, 22, 31).
|
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Our findings support the concept that ET-1-phospholipase coupling is
operative over the concentration range that induces contractile responses in porcine coronary arteries. Short-circuiting membrane channel mechanisms with -toxin did not shift the
concentration-response relation to the right, as would be predicted for
a phospholipase coupling mechanism having a lower sensitivity to ET-1
than a channel mechanism. Moreover,
[32P]PA levels
increase significantly in intact arteries exposed to ET-1 at
concentrations less than the EC50
for contraction. A maximal contraction to ET-1 occurred only when
[Ca]i was elevated above basal levels, thus demonstrating an interactive process between
ET-1-induced Ca entry via membrane channel mechanisms and Ca
sensitization of the contractile system by phospholipase activation and
subsequent signal transduction processes. The existence of such a
process is supported as well by the literature discussed below.
Several studies have established that the predominant ET-1 receptor in
porcine coronary arteries is of the
ETA type (15, 38, 52). The
application of an ETA-selective
antagonist (BQ-123) and
ETB-selective agonist (IRL-1620)
indicated that 10-20% of the contractile response may be mediated
by ETB receptors (15, 52). The
molecular evidence indicates that both receptor types are members of
the G protein-coupled superfamily of receptors and that activation of
either receptor activates PLC (35). It appears that agonist recognition
is the major functional difference between the receptors. We used ET-1
in this study because it binds to both receptor types with high
affinity (dissociation constant 0.1-0.3 nM) (13, 30).
It is of interest that the concentration required for the
EC50 contractile response noted
above is higher than that required for half-maximal occupation of
receptors by a ligand. It has been suggested that internalization of
occupied receptors significantly reduces the number of receptors
available for G protein linkages (13, 32). Thus, unlike -adrenergic receptors in the rat aorta, few spare receptors are available to ET-1
under conditions of prolonged exposure to high concentrations (e.g., 1 h at 1 nM or greater) (13, 55). For this reason, we limited
our measures of
[32P]PA to 10-min
exposures to ET-1.
The coronary arteries are composed of three major cell types, endothelium, smooth muscle, and fibroblasts (2). The endothelial monolayer typically contributes <10% of the cell mass in distributing arteries, whereas the fibroblasts are found for the most part in the adventitia. The first autoradiographic study of human and porcine coronary arteries showed the specific high-affinity binding of 125I-labeled ET to be localized in the media with no detectable endothelial contribution (47). The perivascular binding was localized to nerves (which would be removed by our dissection). Quantitative autoradiography showed the binding sites to be of the ETA receptor type in human aorta and coronary arteries as well as in rat aorta and carotid and cerebral arteries (2, 6). These observations are consistent with other techniques (15, 38, 52). The application of electron microscope autoradiography allowed the binding of 125I-labeled ET-1 to be localized to smooth muscle membranes in human coronary arteries, with ETA receptor binding accounting for 95% of the total (50). Surprisingly little binding was observed in endothelial cells (50). None of the above-cited references reported significant binding of ET-1 to medial or adventitial fibroblasts. Therefore, our assumption that >90% of the [32P]PA responses to ET-1 were from smooth muscle appears to be reasonable on the basis of the autoradiographic evidence.
It is well documented that ET-1 causes an increase in phospholipase products and metabolites in vascular cells, including the PLC products inositol 1,4,5-trisphosphate and DAG, the phospholipase A2 (PLA2) product arachidonic acid, and the PLD product phosphatidylethanol (7, 34, 48, 49, 56, 60). ET-1 also induced increases in [32P]PA, which could either result from the action of PLD on phospholipids (e.g., phosphatidylcholine) or be produced secondarily from the phosphorylation of DAG (22, 31). De novo synthesis of PA from glucose represents a third pathway that can produce [32P]PA, which is important to our assumptions, since this pathway does not involve phospholipase activity (19).
The de novo synthesis of PA and DAG (via phosphatidate phosphohydrolase) has been measured in relevant vascular cell types (16, 33, 62). Increased extracellular glucose or glyceraldehyde stimulated DAG formation in cultured vascular endothelial and smooth muscle cells, with a delay of 1 day for the response to glucose and 4 h for that to glycerol (16, 62). A 3-day exposure to high glucose was required to reach a steady state, which is too slow to explain acute effects of ET-1 on [32P]PA via de novo synthesis. Unfortunately, direct measures of agonist effects on de novo synthesis (e.g., [14C]glucose incorporation into PA) have not been made. It has been suggested that ANG II-induced PA formation by cardiac fibroblasts resulted in part from de novo synthesis (3). The evidence was indirectly based on the incomplete effect of protein kinase C (PKC) downregulation and DAG kinase blockade on ANG II-stimulated PA formation. On the other hand, direct measures of de novo synthesis of PA in fibroblasts showed no significant change in ras-transformed cells that exhibited a fivefold increase in PA concentration (33).
Stimulation of de novo synthesis with high glucose selectively incorporated palmitate, rather than arachidonate and phosphatidylcholine, into DAG of cultured rat aortic smooth muscle cells (62). On the other hand, stimulation of rat arteries with norepinephrine increased PA enriched with arachidonate (43). We also observed a significant increase in [3H]myristate PA in response to ET-1 stimulation of rat aorta in which phosphatidylcholine was selectively labeled (31). These responses argue against (but do not disprove) a major role for de novo synthesis of PA during acute responses in intact arteries. We feel that the use of [32P]PA as a measure of phospholipase activity is justified. A need exists, however, for a systematic study to resolve the quantitative contribution and time course of the multiple pathways that lead to PA production.
Correlations between the sensitivity of phospholipase activity and functional end points to ET-1 have been inconsistent. Two laboratories have emphasized that direct activation of Ca and nonselective cation channels by ET receptors occurred at lower ET-1 concentrations than did the production of phospholipase products and that comparison of ET-1 concentration-response curves commonly have shown that the production of phospholipase products is to the right of that for contraction (8, 9, 24, 31, 40, 48). However, significant increases in phospholipase products have been observed in cultured smooth muscle cells exposed to low concentrations of ET-1 (<1 nM) (12, 40). Our measures of [32P]PA in native arteries (Fig. 6) showed that receptor-coupled activation of phospholipase activity occurred at an ET-1 concentration significantly below the EC50 for contraction. This stimulation of PA production has the potential to interact with the ET-1 effects on Ca entry via ion channels by increasing DAG and PKC activity, which has been linked to Ca sensitization (42, 46, 57, 63).
The specific role of PA in Ca sensitization is not established. First, it is well recognized that PA can result from the phosphorylation of DAG and thus would be an intermediary in the resynthesis of membrane phospholipids (22). Second, PA can be produced directly by the action of PLD on phospholipids (mostly phosphatidylcholine) and could be a source of DAG via the action of phosphatidate phosphohydrolase (22, 34). Third, a growing literature supports the concept that PA directly affects responses of non-smooth muscle cells. For instance, PA activated NADPH oxidase and PLD (a self-amplification process) (1, 4). PA also has been proposed to interact with selective receptors coupled to PLC and to PLA2 (10, 20, 45, 51). The extent to which PA functions as a metabolic intermediate, a second messenger, and/or a ligand for receptor activation of phospholipases in coronary arteries is unknown at this time.
The time course for PA production (Fig. 5) does not rule out a direct role for PA in coupling ET-1 receptor interactions with contractile responses. At high ET-1 (100 nM), significant increases in [32P]PA occurred during the rapid phase of tension development, as would be expected if phospholipase activation were part of the early signaling process (12, 31, 35, 46, 57, 63). The time course at low ET-1 (1 nM) exhibited a delay (>2 min; Fig. 5) in both the [32P]PA and the tension responses. As in the case of high ET-1, significant increases of [32P]PA occurred during tension development at low ET-1 (1 nM), consistent with the hypothesis that phospholipase activation contributed to the contractile response over a wide range of ET-1.
A systematic study of
[Ca]i-tension
relations in intact porcine coronary arteries derived the time course
as a function of ET-1 concentration (59). Initially, the tension
responses to ET-1 were much slower than changes in
[Ca]i. After some
point in time (depending on ET-1 concentration), the tension responses exceeded that predicted from the
[Ca]i-tension relation
for K depolarization. This increased tension response during constant or decreasing [Ca]i
indicated that an increase in Ca sensitivity had occurred (59). The Ca
sensitization began at between 1 and 2 min of exposure to high ET-1
(100 nM) and between 12 and 15 min of exposure to low ET-1 (1 nM) (Fig.
5 in Ref. 59). The timing of this response is consistent with our
measures of increased [32P]PA at 1 min in
ET-1 = 100 nM but not until 5 min in ET-1 = 1 nM (Fig.
5B). It therefore appears that low
concentrations of ET-1 can sensitize the contractile system to
[Ca]i in intact
coronary arteries, as well as in -toxin-permeabilized preparations
(Fig. 3).
It is well established that ET-1 also stimulates Ca influx into
vascular cells (35, 46, 61). Several studies have shown that
45Ca uptake is sensitive to ET-1,
with significant stimulation occurring below 1 nM (23, 40).
Electrophysiological studies have shown that ET-1 causes a
concentration-dependent depolarization in smooth muscle cells with an
EC50 between 0.6 and 1 nM (28,
41). The activation of Ca channels was suggested to cause this
depolarization because whole cell Ba currents were increased over
threefold by ET-1 (11). These currents were blocked by a high
concentration of nicardipine, which also shifted the ET-1-tension
response curve 100-fold to the right (11). In another study, it was
noted that ET-1 increased the Ba currents with an
EC50 of 0.6 nM (18). These
findings are consistent with the proposal that ET-1 at low concentrations activates Ca channels of the L-type (24, 35). Measures
of single-channel activity in the cell-attached mode, however, showed
that the application of ET-1 to the bath increased Ca channel activity
in the patch, which was isolated from the bath solution (18, 53). This
finding indicates that the ET-1 effect on Ca currents may occur via a
second messenger system. As an alternate explanation, internalized
ET-1-receptor complexes could diffuse into the membrane isolated by the
cell-attached patch electrode (13, 32). This possibility has not been
tested. We tried to circumvent such potential problems by
short-circuiting the membrane channels with -toxin.
Additional channel mechanisms have been proposed to underlie ET-1-induced depolarization. ET-1 inhibited the activity of ATP-sensitive K channels (KATP) in porcine coronary smooth muscle (36). Such inhibition was associated with depolarization, which in turn could activate Ca entry via voltage-dependent Ca channels. The IC50 (1.3 nM) for the ET-1 effects on KATP was similar to that observed for other functional end points (36). ET-1 also has been shown to increase membrane conductance and to stimulate inward currents via nonselective cation channels (5, 8). The inward current was sensitive to reduction in extracellular Ca, as well as to other ions, and was blocked by Ni but not by nifedipine (5). This channel type has been identified in various smooth muscles and appears to be activated by receptor-linked G proteins that can be modulated by increases in [Ca]i (17). Hence, ET-1 receptor channel events that initiate depolarization can lead to Ca entry and increased [Ca]i. In turn, this may add to the process by further stimulating Ca-dependent cation channels. Likewise, ET-1-induced Ca release from SR could promote Ca entry via Ca-dependent regulation of nonselective cation channels (61). Thus ET-receptor channel mechanisms and ET-receptor PLC coupling would contribute to Ca entry and dependence of [Ca]i on extracellular Ca concentration during both phasic and tonic responses to ET-1.
In our experiments, the contribution of changes in
[Ca]i to the
contractile process was controlled by buffering
[Ca]i in -toxin permeabilized arteries. With protocols such as that shown in Fig. 1, we
were able to determine the ET-1 concentration dependence of Ca
sensitization at constant
[Ca]i. As shown in
Fig. 3, the EC50 for contraction
in permeabilized vessels was similar to that under intact conditions in
which both Ca entry and Ca sensitization occur. The analysis was
conducted after the ET-1 responses stabilized (tonic response) in
intact vessels. Under these conditions,
[Ca]i is stable or
returns toward basal levels in porcine coronary arteries (59, 61). With
[Ca]i buffered to 0.1 µM, high ET-1 concentrations produced a response that was 61% of
maximal release. To achieve the same level of contraction in the
absence of ET-1, [Ca]i
would need to be raised to 0.6 µM (Fig. 2), a level that can be
observed during complete depolarization of isolated porcine coronary
arteries (29). Commonly, only a twofold increase in
[Ca]i is observed during exposure to agonists. Therefore, it would be difficult to
rationalize near-maximal force development during ET-1 stimulation if
only membrane channels and Ca entry were driving the system. Recent
measures of
[Ca]i-tension
relations in intact porcine coronary arteries showed early contractile
events (
50% maximal) to be driven by changes in
[Ca]i (entry
mechanisms), whereas maximal tension occurred later via Ca
sensitization at ET-1 concentrations
0.3 nM (59). We propose that
both Ca entry and Ca sensitization mechanisms are operative under
physiologically relevant conditions. Rather than operating only at high
ET-1, Ca sensitization mechanisms are essential for normal biological
responses over an extended range of ET-1 concentrations.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Don Wycoff for technical assistance.
![]() |
FOOTNOTES |
---|
This investigation was supported in part by National Heart, Lung, and Blood Institute Grants PO1-HL-52490, RO1-HL-15852, and HL-36531 and by the American Heart Association, Missouri Affiliate.
Address for reprint requests: A. W. Jones, Dept. of Physiology, School of Medicine, MA415, Medical Sciences Bldg., University of Missouri, Columbia, MO 65212.
Received 6 October 1997; accepted in final form 12 March 1998.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Agwu, D. E.,
L. C. McPhail,
S. Sozzani,
D. A. Bass,
and
C. E. McCall.
Phosphatidic acid as a second messenger in human polymorphonuclear leukocytes.
J. Clin. Invest.
88:
531-539,
1991[Medline].
2.
Bacon, C. R.,
and
A. P. Davenport.
Endothelin receptors in human coronary artery and aorta.
Br. J. Pharmacol.
117:
986-992,
1996[Abstract].
3.
Booz, G. W.,
M. M. Taher,
K. M. Baker,
and
H. A. Singer.
Angiotensin II induces phosphatidic acid formation in neonatal rat cardiac fibroblasts: evaluation of the roles of phospholipases C and D.
Mol. Cell. Biochem.
141:
135-143,
1994[Medline].
4.
Bursten, S. L.,
and
W. E. Harris.
Interleukin-1 stimulates phosphatidic acid-mediated phospholipase D activity in human mesangial cells.
Am. J. Physiol.
266 (Cell Physiol. 35):
C1093-C1104,
1994
5.
Chen, C.,
and
P. K. Wagoner.
Endothelin induces a nonselective cation current in vascular smooth muscle cells.
Circ. Res.
69:
447-454,
1991[Abstract].
6.
De Oliveira, A. M.,
M. Viswanathan,
S. Capsoni,
F. M. J. Heemskerk,
F. M. A. Correa,
and
J. M. Saavedra.
Characterization of endothelinA receptors in cerebral and peripheral arteries of the rat.
Peptides
16:
139-144,
1995[Medline].
7.
Eguchi, S.,
Y. Hirata,
M. Ihara,
M. Yano,
and
F. Marumo.
A novel ETA antagonist (BQ-123) inhibits endothelin-1-induced phosphoinositide breakdown and DNA synthesis in rat vascular smooth muscle cells.
FEBS Lett.
302:
243-246,
1992[Medline].
8.
Enoki, T.,
S. Miwa,
A. Sakamoto,
T. Minowa,
T. Komuro,
S. Kobayashi,
H. Ninomiya,
and
T. Masaki.
Long-lasting activation of cation current by low concentration of endothelin-1 in most fibroblasts and smooth muscle cells of rabbit aorta.
Br. J. Pharmacol.
115:
479-485,
1995[Abstract].
9.
Enoki, T.,
S. Miwa,
A. Sakamoto,
T. Minowa,
T. Komuro,
S. Kobayashi,
H. Ninomiya,
and
T. Masaki.
Functional coupling of ETA receptor with Ca2+-permeable nonselective cation channel in mouse fibroblasts and rabbit aortic smooth-muscle cells.
J. Cardiovasc. Pharmacol.
26:
S258-S261,
1995[Medline].
10.
Fernandez, B.,
M. A. Balboa,
J. A. Solis-Herruzo,
and
J. Balsinde.
Phosphatidate-induced arachidonic acid mobilization in mouse peritoneal macrophages.
J. Biol. Chem.
269:
26711-26716,
1994
11.
Goto, K.,
Y. Kasuya,
N. Matsuki,
Y. Takuwa,
H. Kurihara,
T. Ishikawa,
S. Kimura,
M. Yanagisawa,
and
T. Masaki.
Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca2+ channel in vascular smooth muscle.
Proc. Natl. Acad. Sci. USA
86:
3915-3918,
1989[Abstract].
12.
Griendling, K. K.,
T. Tsuda,
and
R. W. Alexander.
Endothelin stimulates diacylglycerol accumulation and activates protein kinase C in cultured vascular smooth muscle cells.
J. Biol. Chem.
264:
8237-8240,
1989
13.
Hirata, Y.,
H. Yoshimi,
S. Takaichi,
M. Yanagisawa,
and
T. Masaki.
Binding and receptor down-regulation of a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells.
FEBS Lett.
239:
13-17,
1988[Medline].
14.
Hori, M.,
K. Sato,
K. Sakata,
H. Ozaki,
H. Takano-Ohmuro,
T. Tsuchiya,
H. Sugi,
I. Kato,
and
H. Karaki.
Receptor agonists induce myosin phosphorylation-dependent and phosphorylation-independent contractions in vascular smooth muscle.
J. Pharmacol. Exp. Ther.
261:
506-512,
1992[Abstract].
15.
Ihara, M.,
K. Noguchi,
T. Saeki,
T. Fukuroda,
S. Tsuchida,
S. Kimura,
T. Fukami,
K. Ishikawa,
M. Nishikibe,
and
M. Yano.
Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor.
Life Sci.
50:
247-255,
1991.
16.
Inoguchi, T.,
P. Xia,
M. Kunisaki,
S. Higashi,
E. P. Feener,
and
G. L. King.
Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues.
Am. J. Physiol.
267 (Endocrinol. Metab. 30):
E369-E379,
1994
17.
Inoue, R.,
and
S. Chen.
Physiology of muscarinic receptor-operated nonselective cation channels in guinea-pig ileal smooth muscle.
In: Nonselective Cation Channels: Pharmacology, Physiology and Biophysics, edited by D. Siemen,
and J. Hescheler. Basel: Virkauser Verlag, 1993, p. 261-268.
18.
Inoue, Y.,
M. Oike,
K. Nakao,
K. Kitamura,
and
H. Kuriyama.
Endothelin augments unitary calcium channel currents on the smooth muscle cell membrane of guinea-pig portal vein.
J. Physiol. (Lond.)
423:
171-191,
1990[Abstract].
19.
Ishii, H.,
D. Koya,
and
G. L. King.
Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus.
J. Mol. Med.
76:
21-31,
1998[Medline].
20.
Jacob, G.,
C. C. Allende,
and
J. E. Allende.
Characteristics of phospholipase C present in membranes of Xenopus laevis oocytes. Stimulation by phosphatidic acid.
Comp. Biochem. Physiol. B Biochem. Mol. Biol.
106B:
895-900,
1993.
21.
Jones, A. W.,
B. B. Geisbuhler,
S. D. Shukla,
and
J. M. Smith.
Altered biochemical and functional responses in aorta from hypertensive rats.
Hypertension
11:
627-634,
1988[Abstract].
22.
Jones, A. W.,
S. D. Shukla,
and
B. B. Geisbuhler.
Stimulation of phospholipase D activity and phosphatidic acid production by norepinephrine in rat aorta.
Am. J. Physiol.
264 (Cell Physiol. 33):
C609-C616,
1993
23.
Kasuya, Y.,
T. Ishikawa,
M. Yanagisawa,
S. Kimura,
K. Goto,
and
T. Masaki.
Mechanism of contraction to endothelin in isolated porcine coronary artery.
Am. J. Physiol.
257 (Heart Circ. Physiol. 26):
H1828-H1835,
1989
24.
Kasuya, Y.,
Y. Takuwa,
M. Yanagisawa,
T. Masaki,
and
K. Goto.
A pertussis toxin-sensitive mechanism of endothelin action in porcine coronary artery smooth muscle.
Br. J. Pharmacol.
107:
456-462,
1992[Abstract].
25.
Kawase, T.,
and
C. Van Breemen.
Aluminum fluoride induces a reversible Ca2+ sensitization in -toxin-permeabilized vascular smooth muscle.
Eur. J. Pharmacol.
214:
39-44,
1992[Medline].
26.
Kobayashi, S.,
M. C. Gong,
A. V. Somlyo,
and
A. P. Somlyo.
Ca2+ channel blockers distinguish between G protein-coupled pharmacomechanical Ca2+ release and Ca2+ sensitization.
Am. J. Physiol.
260 (Cell Physiol. 29):
C364-C370,
1991
27.
Kodama, M.,
H. Yamamoto,
and
H. Kanaide.
Myosin phosphorylation and Ca2+ sensitization in porcine coronary arterial smooth muscle stimulated with endothelin-1.
Eur. J. Pharmacol.
288:
69-77,
1994[Medline].
28.
Korbmacher, C.,
H. Helbig,
H. Haller,
K. A. Erickson-Lamy,
and
M. Wiederholt.
Endothelin depolarizes membrane voltage and increases intracellular calcium concentration in human ciliary muscle cells.
Biochem. Biophys. Res. Commun.
164:
1031-1039,
1989[Medline].
29.
Kuroiwa, M.,
H. Aoki,
S. Kobayashi,
J. Nishimura,
and
H. Kanaide.
Role of GTP-protein and endothelium in contraction induced by ethanol in pig coronary artery.
J. Physiol. (Lond.)
470:
521-537,
1993[Abstract].
30.
LaDouceur, D. M.,
M. A. Flynn,
J. A. Keiser,
E. Reynolds,
and
S. J. Haleen.
ETA and ETB receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction.
Biochem. Biophys. Res. Commun.
196:
209-215,
1993[Medline].
31.
Liu, Y.,
B. Geisbuhler,
and
A. W. Jones.
Activation of multiple mechanisms including phospholipase D by endothelin-1 in rat aorta.
Am. J. Physiol.
262 (Cell Physiol. 31):
C941-C949,
1992
32.
Marsault, R.,
E. Feolde,
and
C. Frelin.
Receptor externalization determines sustained contractile responses to endothelin-1 in the rat aorta.
Am. J. Physiol.
264 (Cell Physiol. 33):
C687-C693,
1993
33.
Martin, A.,
P. A. Duffy,
C. Liossis,
A. Gomez-Muñoz,
L. O'Brien,
J. C. Stone,
and
D. N. Brindley.
Increased concentrations of phosphatidate, diacylglycerol and ceramide in ras- and tyrosine kinase (fps)-transformed fibroblasts.
Oncogene
14:
1571-1580,
1997[Medline].
34.
Martin, T. W.
Formation of diacylglycerol by a phospholipase D-phosphatidate phosphatase pathway specific for phosphatidylcholine in endothelial cells.
Biochim. Biophys. Acta
962:
282-296,
1988[Medline].
35.
Masaki, T.
Possible role of endothelin in endothelial regulation of vascular tone.
Annu. Rev. Pharmacol. Toxicol.
35:
235-255,
1995[Medline].
36.
Miyoshi, Y.,
Y. Nakaya,
T. Wakatsuki,
S. Nakaya,
K. Fujino,
K. Saito,
and
I. Inoue.
Endothelin blocks ATP-sensitive K+ channels and depolarizes smooth muscle cells of porcine coronary artery.
Circ. Res.
70:
612-616,
1992[Abstract].
37.
Moreland, R. S.,
and
R. A. Murphy.
Determinants of Ca2+-dependent stress maintenance in skinned swine carotid media.
Am. J. Physiol.
251 (Cell Physiol. 20):
C892-C903,
1986
38.
Moreland, S.
BQ-123, a selective endothelin ETA receptor antagonist.
Cardiovasc. Drug Rev.
12:
48-69,
1994.
39.
Moreland, S.,
J. Nishimura,
C. Van Breemen,
H. Y. Ahn,
and
R. S. Moreland.
Transient myosin phosphorylation at constant Ca2+ during agonist activation of permeabilized arteries.
Am. J. Physiol.
263 (Cell Physiol. 32):
C540-C544,
1992
40.
Muldoon, L. L.,
H. Enslen,
K. D. Rodland,
and
B. E. Magun.
Stimulation of Ca2+ influx by endothelin-1 is subject to negative feedback by elevated intracellular Ca2+.
Am. J. Physiol.
260 (Cell Physiol. 29):
C1273-C1281,
1991
41.
Nakao, K.,
Y. Inoue,
M. Oike,
K. Kitamura,
and
H. Kuriyama.
Mechanisms of endothelin-induced augmentation of the electrical and mechanical activity in rat portal vein.
Pflügers Arch.
415:
526-532,
1990[Medline].
42.
Nishimura, J.,
S. Moreland,
H. Y. Ahn,
T. Kawase,
R. S. Moreland,
and
C. van Breemen.
Endothelin increases myofilament Ca2+ sensitivity in -toxin-permeabilized rabbit mesenteric artery.
Circ. Res.
71:
951-959,
1992[Abstract].
43.
Ohanian, J.,
J. Ollerenshaw,
P. Collins,
and
A. Heagerty.
Agonist-induced production of 1,2-diacylglycerol and phosphatidic acid in intact resistance arteries.
J. Biol. Chem.
265:
8921-8928,
1990
44.
Pang, D. C., A. Johns, K. Patterson, L. H. Parker-Botelho, and G. M. Rubanyi. Endothelin-1
stimulates phosphatidylinositol hydrolysis and calcium uptake in
isolated canine coronary arteries. J. Cardiovasc.
Pharmacol. 13, Suppl. 5: S75-S79,
1989.
45.
Pearce, B.,
K. Jakobson,
C. Morrow,
and
S. Murphy.
Phosphatidic acid promotes phosphoinositide metabolism and DNA synthesis in cultured cortical astrocytes.
Neurochem. Int.
24:
165-171,
1994[Medline].
46.
Pollock, D. M.,
T. L. Keith,
and
R. F. Highsmith.
Endothelin receptors and calcium signaling.
FASEB J.
9:
1196-1204,
1995
47.
Power, R. F.,
J. Wharton,
S. P. Salas,
S. Kanse,
M. Ghatei,
S. R. Bloom,
and
J. M. Polak.
Autoradiographic localisation of endothelin binding sites in human and porcine coronary arteries.
Eur. J. Pharmacol.
160:
199-200,
1989[Medline].
48.
Rapoport, R. M.,
K. A. Stauderman,
and
R. F. Highsmith.
Effects of EDCF and endothelin on phosphatidylinositol hydrolysis and contraction in rat aorta.
Am. J. Physiol.
258 (Cell Physiol. 27):
C122-C131,
1990
49.
Resink, T. J.,
T. Scott-Burden,
and
F. R. Bühler.
Activation of multiple signal transduction pathways by endothelin in cultured human vascular smooth muscle cells.
Eur. J. Biochem.
189:
415-421,
1990[Abstract].
50.
Russell, F. D.,
J. N. Skepper,
and
A. P. Davenport.
Detection of endothelin receptors in human coronary artery vascular smooth muscle cells but not endothelial cells by using electron microscope autoradiography.
J. Cardiovasc. Pharmacol.
29:
820-826,
1997[Medline].
51.
Ryder, N. S.,
H. S. Talwar,
N. J. Reynolds,
J. J. Voorhees,
and
G. J. Fisher.
Phosphatidic acid and phospholipase D both stimulate phosphoinositide turnover in cultured human keratinocytes.
Cell. Signal.
5:
787-794,
1993[Medline].
52.
Shetty, S. S.,
T. Okada,
R. L. Webb,
D. DelGrande,
and
R. W. Lappe.
Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle.
Biochem. Biophys. Res. Commun.
191:
459-464,
1993[Medline].
53.
Silberberg, S. D.,
T. C. Poder,
and
A. E. Lacerda.
Endothelin increases single-channel calcium currents in coronary arterial smooth muscle cells.
FEBS Lett.
247:
68-72,
1989[Medline].
54.
Smith, G. L.,
and
C. A. Crichton.
Ca-EGTA affects the relationship between [Ca2+] and tension in -toxin permeabilized rat anococcygeus smooth muscle.
J. Muscle Res. Cell Motil.
14:
76-84,
1993[Medline].
55.
Smith, J. M.,
S. B. Jones,
D. B. Bylund,
and
A. W. Jones.
Characterization of the -1 adrenergic receptors in the thoracic aorta of control and aldosterone hypertensive rats: correlation of radioligand binding with potassium efflux and contraction.
J. Pharmacol. Exp. Ther.
241:
882-890,
1987[Abstract].
56.
Sunako, M.,
Y. Kawahara,
K. Hirata,
T. Tsuda,
M. Yokoyama,
H. Fukuzaki,
and
Y. Takai.
Mass analysis of 1,2-diacylglycerol in cultured rabbit vascular smooth muscle cells.
Hypertension
15:
84-88,
1990[Abstract].
57.
Tanaka, Y.,
H. Ishiro,
T. Nakazawa,
M. Saito,
K. Ishii,
and
K. Nakayama.
Potentiation by endothelin-1 of Ca2+ sensitivity of contractile elements depends on Ca2+ influx through L-type Ca2+ channels in the canine cerebral artery.
Gen. Pharmacol.
26:
855-864,
1995[Medline].
58.
Trinkle-Mulcahy, L.,
M. J. Siegman,
and
T. M. Butler.
Metabolic characteristics of -toxin-permeabilized smooth muscle.
Am. J. Physiol.
266 (Cell Physiol. 35):
C1673-C1683,
1994
59.
Ushio-Fukai, M.,
J. Nishimura,
S. Kobayashi,
and
H. Kanaide.
Endothelin-1 and endothelin-3 regulate differently vasoconstrictor responses of smooth muscle of the porcine coronary artery.
Br. J. Pharmacol.
114:
171-179,
1995[Abstract].
60.
Van Reterghem, C.,
P. Vigne,
J. Barhanin,
A. Schmid-Alliana,
C. Frelin,
and
M. Lazdunski.
Molecular mechanism of action of the vasoconstrictor peptide endothelin.
Biochem. Biophys. Res. Commun.
157:
977-985,
1988[Medline].
61.
Wagner-Mann, C.,
and
M. Sturek.
Endothelin mediates Ca influx and release in porcine coronary smooth muscle cells.
Am. J. Physiol.
260 (Cell Physiol. 29):
C771-C777,
1991
62.
Xia, P.,
T. Inoguchi,
T. S. Kern,
R. L. Engerman,
P. J. Oates,
and
G. L. King.
Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia.
Diabetes
43:
1122-1129,
1994[Abstract].
63.
Yasida, M.,
A. Suzuki,
and
T. Itoh.
Mechanisms of vaso-constriction induced by endothelin-1 in smooth muscle of rabbit mesenteric artery.
J. Physiol. (Lond.)
477:
253-265,
1994[Abstract].